How do DOACs compare with vitamin K antagonists?

Comparable protection against venous thromboembolism (VTE) recurrence, less overall risk of bleeding (especially intracranial bleeding). Studies have shown that gastrointestinal bleeding may be increased in patients taking DOAC but these studies involve cohorts with atrial fibrillation, not VTE.